The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.

Chiara CiccareseAnnunziato AngheloneAlessio StefaniAntonio CigliolaAlessandro StrusiFilippo D'AgostinoEmilio BriaRoberto IacovelliGiampaolo Tortora

Published in: Expert review of anticancer therapy (2024)

ICI+TKI combinations increase the risk of MACEs compared to controls, although the absolute incidence is eventually low. Routine cardiovascular monitoring in asymptomatic patients is therefore not recommended.

Keyphrases

cardiovascular events
end stage renal disease
risk factors
coronary artery disease
ejection fraction
blood pressure
chronic kidney disease
cardiovascular disease
peritoneal dialysis
tyrosine kinase
emergency department
patient reported outcomes
epidermal growth factor receptor
patient reported